drugset / Trial / NCT00302627
Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation
Completed
43 enrolled
Providence Health & Services
Ochsner Health System · collabThe Heart Institute of Spokane · collabUniversity of Washington · collab
NaSingle-groupOpen-labelTreatment
Summary
Bone is lost rapidly and fractures occur in 10-20% of patients who receive organ transplants within 2 years. The purpose of this study is to evaluate long-term effects of a pamidronate-vitamin D-calcium regimen on bone loss, fractures, and safety in recipients of kidney and heart transplants.
Timeline
- Start
- 1999-01
- Primary completion
- 2002-11
- Completion
- 2002-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcium carbonate | Other / unclassified | 1500 mg | — |
| Subject | Pamidronate | Small molecule | 60 mg | Intravenous |
| Subject | Pamidronate | Small molecule | 90 mg | Intravenous |
| Subject | Vitamin D | Other / unclassified | 800 iu | — |